In focus · trending topic

Ultragenyx Pharmaceutical Inc.

2 stories · following the connections

Ultragenyx to Highlight Pipeline at Analyst and Investor Day on December 4

By Nasdaq OMXNov 30, 2017, 1:31 PM UTC

Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency

By Nasdaq OMXNov 16, 2017, 1:30 PM UTC